Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C9H11NO2 |
Molecular Weight | 165.1891 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CC=CC=C1)C(O)=O
InChI
InChIKey=COLNVLDHVKWLRT-QMMMGPOBSA-N
InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1
Molecular Formula | C9H11NO2 |
Molecular Weight | 165.1891 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Phenylalanine is a biologically essential amino acid that acts as a precursor to tyrosine and the catecholamines (epinephrine, norepinephrine, dopamine, and tyramine), and is a constituent
of many central nervous system neuropeptides. Normal dietary levels of phenylalanine are approximately 1-2 grams daily. Phenylalanine appears in two forms which are identical mirror images of each other: L-phenylalanine, a nutritional supplement, and D-phenylalanine, an effective painkiller and antidepressant due to its ability to inhibit the breakdown of enkephalins, the brain’s natural pain killers.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3076 |
|||
Target ID: CHEMBL1907608 |
1.71 mM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | FREAMINE III 10% Approved UseParenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is
indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric
patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or
should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal
absorption of protein is impaired; or (3) protein requirements are substantially increased as with
extensive burns. Dosage, route of administration, and concomitant infusion of non-protein
calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance Launch Date1971 |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1389 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11244252/ |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENYLALANINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
35.7 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11244252/ |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENYLALANINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11244252/ |
20 mg/kg single, intravenous dose: 20 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
PHENYLALANINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Ten novel mutations in the phenylalanine hydroxylase gene (PAH) observed in Brazilian patients with phenylketonuria. | 2001 |
|
Self-association of the H3 region of syntaxin 1A. Implications for intermediates in SNARE complex assembly. | 2001 Apr 20 |
|
Reaction of oxidized dopamine with endogenous cysteine residues in the human dopamine transporter. | 2001 Feb |
|
Auto-inhibition of Ca(2+)/calmodulin-dependent protein kinase II by its ATP-binding domain. | 2001 Feb |
|
In vivo protein synthetic rates of atrial, ventricular, and pulmonary tissue proteins in aortic constriction, goldblatt, and bromoethylamine models of hypertension. | 2001 Feb |
|
Cloning of dopamine, norepinephrine and serotonin transporters from monkey brain: relevance to cocaine sensitivity. | 2001 Feb 19 |
|
Kynurenine aminotransferase I activity in human placenta. | 2001 Feb-Mar |
|
The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. | 2001 Jan |
|
Physical stability of the blue pigments formed from geniposide of gardenia fruits: effects of pH, temperature, and light. | 2001 Jan |
|
New analogues of bradykinin containing a conformationally restricted dipeptide fragment in their molecules. | 2001 Jan |
|
The unique tryptophan residue of the vitamin D receptor is critical for ligand binding and transcriptional activation. | 2001 Jan |
|
The protein-retaining effects of growth hormone during fasting involve inhibition of muscle-protein breakdown. | 2001 Jan |
|
Characterization of 3-[(123)I]iodo-L-alpha-methyl tyrosine transport in astrocytes of neonatal rats. | 2001 Jan |
|
A study of peptide--peptide interaction by matrix-assisted laser desorption/ionization. | 2001 Jan |
|
An in vivo study of ovine placental transport of essential amino acids. | 2001 Jan |
|
Amino acid phosphoramidate monoesters of 3'-azido-3'-deoxythymidine: relationship between antiviral potency and intracellular metabolism. | 2001 Jan 18 |
|
A single arginyl residue in plastocyanin and in cytochrome c(6) from the cyanobacterium Anabaena sp. PCC 7119 is required for efficient reduction of photosystem I. | 2001 Jan 5 |
|
Acute effects of peritoneal dialysis with dialysates containing dextrose or dextrose and amino acids on muscle protein turnover in patients with chronic renal failure. | 2001 Mar |
|
Selected Contribution: IGF-I antibody prevents increases in protein synthesis in epitrochlearis muscles from refed, diabetic rats. | 2001 Mar |
|
A possible role for metalloproteinases in renal cyst development. | 2001 Mar |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.cpmedical.net/pdf/Phenylalanine.pdf
L-Phenylalanine Capsules (400 mg/cap): one to two capsules per day on an empty stomach.
L-Phenylalanine Powder: 480 mg one to two times per day on an empty stomach.
DL-Phenylalanine Capsules (500 mg/cap): one capsule daily on an empty stomach.
DL-Phenylalanine Powder: 1/8 level teaspoon two to three times daily on an empty stomach.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11986979
In cultured hippocampal neurons from newborn rats L-phenylalanine specifically and reversibly attenuated NMDA-activated currents in a concentration-dependent manner (IC50=1.71 mM)
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:06:13 GMT 2023
by
admin
on
Fri Dec 15 15:06:13 GMT 2023
|
Record UNII |
47E5O17Y3R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
53396-8
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
53151-7
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
13893-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
53398-4
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
29573-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
74481-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
CFR |
21 CFR 201.21
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
53157-4
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
27362-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
47981-6
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
32263-6
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
55970-8
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
47724-0
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
26981-1
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
14875-9
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
JECFA EVALUATION |
L-PHENYLALANINE
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
47721-6
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
30055-8
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
25970-5
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
44349-9
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
53156-6
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
12803-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
26967-0
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
22646-4
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
2764-9
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
20653-2
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
41170-2
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
22683-7
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
49484-9
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
DSLD |
1580 (Number of products:829)
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
2763-1
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
2766-4
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
32265-1
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
53394-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
DSLD |
169 (Number of products:17)
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
47722-4
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
38495-8
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
2762-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
25495-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
57995-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
47725-7
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
44348-1
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
13409-8
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
21057-5
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
53153-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
21056-7
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
75268-3
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
35572-7
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
47723-2
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
29571-7
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
55969-0
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
25969-7
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
22737-1
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
CFR |
21 CFR 201.66
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
32264-4
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
53392-7
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
18475-4
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
2768-0
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
53393-5
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
2767-2
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
29572-5
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
||
|
LOINC |
2765-6
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1825
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
2144
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
200-568-1
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
C29601
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
1418
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
D010649
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
6140
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
6168
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
58095
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
100000092416
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
47E5O17Y3R
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL301523
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
63-91-2
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
29997
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
DB00120
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
8156
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB32327
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
SUB09786MIG
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
79477
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
PHENYLALANINE
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
1530503
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
17295
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
47E5O17Y3R
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
m8652
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
28044
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY | |||
|
DTXSID4040763
Created by
admin on Fri Dec 15 15:06:13 GMT 2023 , Edited by admin on Fri Dec 15 15:06:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
DEGRADENT -> PARENT |
Precursor is Phenylalanine
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
RECOMBINANT ORGANISM->SUBSTRATE | |||
|
ENZYME->SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
LABELED -> NON-LABELED |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET | |||
|
DERIVATIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
||
|
PARENT -> METABOLITE |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
PARENT -> IMPURITY |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
PARENT -> IMPURITY |
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
||
|
PARENT -> IMPURITY |
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|